Navigation Links
Researchers find alternative cholesterol-lowering drug for patients who can't tolerate statins
Date:3/11/2013

SAN FRANCISCO Heart patients who can't tolerate the side effects of cholesterol-lowering drugs may have a new option, according to a new study by researchers from the Intermountain Heart Institute at Intermountain Medical Center in Salt Lake City.

Researchers found that pitavastatin, a newer cholesterol-lowering drug, may reduce the risk of heart attack, stroke and even death in up to 68 percent of patients with high cholesterol who can't tolerate other cholesterol-lowering medications due to side effects.

Researchers are presenting the results of this study today (Monday, March 10) at the American College of Cardiology's Annual Scientific Session in San Francisco.

The findings are important because up to 15 percent of the nation's heart patients can't tolerate other statin medications, currently the most effective cholesterol-lowering agents available.

"Many of the patients who were not able to tolerate other statins developed side effects, such as myalgia or severe muscle aches. However, our study shows that pitavastatin may be a more tolerable statin that patients can take that will be effective in lowering their cholesterol, and may even save their lives," said Brent Muhlestein, MD, cardiologist at the Intermountain Heart Institute at Intermountain Medical Center, and lead researcher for the study.

The Research

The research team identified 40 patients who had tried at least two other statins and tested them to see if they could tolerate pitavastatin, and if it was effective in lowering their LDL or "bad" cholesterol.

All patients received initial baseline testing, including fasting LDL cholesterol levels. They were then given 2 mg of pitavastatin (also known as Livalo), per day. Those who could tolerate it were then tested again to see if their LDL cholesterol had been reduced.

Findings

  • 68 percent of the study participants were able to tolerate the side-effects of pitavastatin.

  • Pitavastatin lowered cholesterol by an average of 34 percent.

  • Patients who could best tolerate the drug were males with no history of heart disease or diabetes.

"We're excited about these findings," said Dr. Muhlestein. "If patients are having a hard time taking older statins, they should try this newer option. We believe the side effects of this drug differ from other statins because pitavastatin is water-soluble and metabolizes differently."

The Intermountain study also confirmed that pitavastatin is far more effective than any other non-statin option.

Ezetimibe (Zetia), for example, is a drug that blocks the absorption of cholesterol and is a non-statin treatment option, but it only lowers bad cholesterol by 18 to 20 percent. Another option is healthy margarine, but that only lowers it by 5 to 10 percent. Pitavastatin, by contrast, lowered cholesterol by an average of 34 percent, according to the study.


'/>"/>

Contact: Jess C. Gomez
jess.gomez@imail.org
801-718-8495
Intermountain Medical Center
Source:Eurekalert

Related biology news :

1. Researchers develop tools for discovering new species
2. University of Illinois researchers develop AFM-IR for nanometer scale chemical identification
3. IRB Barcelona researchers discover mechanism that regulates steroid hormone production in Drosophila
4. Researchers discover gateway in nucleus has a second important job no one noticed before
5. Researchers explain a key developmental mechanism for the first time in plants
6. Researchers find molecular switch turning on self-renewal of liver damage
7. UGA researchers shed light on ancient origin of life
8. Researchers discover workings of brains GPS system
9. Researchers propose new solution to ensure biofuel plants dont become noxious weeds
10. Temple researchers discover key to heart failure, new therapies on horizon
11. Researchers discover gene that causes obesity in mice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2016)... 20, 2016  Synaptics Incorporated (NASDAQ: SYNA ... today announced sampling of S1423, its newest ClearPad ... small screen applications including smartwatches, fitness trackers, and ... and rectangular shapes, as well as thick and ... moisture on screen, while wearing gloves, and supports ...
(Date:1/15/2016)... , Jan. 15, 2016 Recent publicized ... small to find new ways to ensure data security ... iOS and Android that ties ... biometrics, transforming it into a hardware authorization token. Customer ... swipe their fingerprint on their KodeKey enabled device to ...
(Date:1/13/2016)... , January 13, 2016 /PRNewswire/ ... announced the addition of the  "India ... Estimation & Forecast (2015-2020)"  report ... http://www.researchandmarkets.com/research/7h6hnn/india_biometrics ) has announced the addition ... Identification Market - Estimation & Forecast ...
Breaking Biology News(10 mins):
(Date:2/8/2016)... , February 8, 2016 ... Genetics" or the "Company"), the ultra-rapid Point-Of-Care (POC) molecular diagnostics ... Mark its Chlamydia trachomatis (CT) test to be launched on ... IVD Directive (98/79/EC), the CT test is now cleared for ... --> The launch of the io® CT test ...
(Date:2/6/2016)... Virginia (PRWEB) , ... February 06, 2016 , ... ... E-mail: amitchell(at)cee(dot)org , The Center for Excellence in Education Sponsors Teacher Training ... VA – February 4, 2016 – The Center for Excellence in Education (CEE) ...
(Date:2/5/2016)... CHAPEL HILL, N.C. , Feb. 5, 2016 /PRNewswire/ ... a key role for a host of launch activities ... The importance of this launch activity is especially high ... are specialists. Best Practices and the Role ... study will help companies focused on oncology therapies find ...
(Date:2/5/2016)... -- Amarantus BioScience Holdings, Inc. ... products for Regenerative Medicine, Neurology and Orphan Diseases, announced ... from the US Food and Drug Administration (FDA) for ... granted orphan drug designation (ODD) by the US FDA ... Inc. (OTCQB: AMBS), a biotechnology company ...
Breaking Biology Technology: